Disclaimer
The recommendations provided by the authors were presented on November 6, 2015, at the annual national meeting of Mentoring in IBD: The Master Class in Toronto, Ontario. The opinions and recommendations do not necessarily accurately reflect the current state of affairs or the current advice the authors may choose to provide in the same circumstances. Please refer to the current guidelines or the Canadian Association of Gastroenterology for up-to-date treatment options.
Learning Objectives
The educational objective of Mentoring in IBD is to increase awareness of current developments and best practices in inflammatory bowel disease (IBD) management, promote collaboration among Canadian gastroenterologists, and optimize treatment of IBD.
Participants in this program will be able to:
- Assess the state of mental health in IBD patients and develop pragmatic approaches to address and manage mental health issues
- Determine when and how to switch from one biologic agent to another to optimize management of IBD
- Appraise the efficacy of dietary therapies in IBD
- Examine the rules of stopping biologics in IBD therapy from the perspectives of the North American and European environments
- Evaluate two clinical trials that will change post-operative practice in IBD
- Survey current IBD literature
Mental Health and IBD
Presented by Rebecca Anglin
Workshop Case
Abstract and References
State-of-the-art Plenary Presentation
Optimizing Management in IBD: Switching Biologics
Presented by Edward V. Loftus Jr
Workshop Case
Abstract and References
State-of-the-art Plenary Presentation
Vitamin D in IBD
Presented by Khursheed Jeejeebhoy
Abstract and References
State-of-the-art Plenary Presentation
The Rules of Stopping Biologics: A European Perspective
Presented by Alessandro Armuzzi
Workshop Case
Abstract and References
State-of-the-art Plenary Presentation
The Rules of Stopping Biologics: A North American Perspective
Presented by Brian Feagan
Workshop Case
Abstract and References
State-of-the-art Plenary Presentation
PREVENT Study Data: Infliximab in the postoperative Crohn's disease environment
Presented by A. Hillary Steinhart
Abstract and References
State-of-the-art Plenary Presentation
POCER Study Data: Adalimumab in the postoperative Crohn's disease environment
Presented by Geoffrey Nguyen
Abstract and References
State-of-the-art Plenary Presentation